Status:
COMPLETED
DEB-TACE Treatment in 367 Liver Cancer Patients
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its high...
Eligibility Criteria
Inclusion
- Diagnosed as primary HCC, primary ICC or secondary liver cancer confirmed by pathological findings, clinical features or radiographic examinations according to American Association for the Study of the Liver Diseases (AASLD) guidelines;
- Age above 18 years;
- About to receive DEB-TACE treatment with CalliSpheres® according to clinical needs and patients' willing.
- Able to be followed up regularly;
- Life expectancy above 12 months.
Exclusion
- History of liver transplantation;
- History of hematological malignances;
- Severe hepatic failure or renal failure;
- Contraindication for angiography, embolization procedure or artery puncture;
- Patients with cognitive impairment, or unable to understand the study consents.
- Women in gestation or lactation period.
Key Trial Info
Start Date :
November 12 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 28 2016
Estimated Enrollment :
367 Patients enrolled
Trial Details
Trial ID
NCT03317483
Start Date
November 12 2015
End Date
December 28 2016
Last Update
October 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.